Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
March 20, 2024 08:30 ET | Silo Pharma, Inc.
Exclusive license for development, manufacturing, and commercialization in process Silo Pharma to file Pre-IND in first half 2024 SARASOTA, FL, March 20, 2024 (GLOBE NEWSWIRE) --  Silo Pharma,...
Global Post-traumatic Stress Disorder (PTSD) Drug Pipeline Landscape Report 2024 Featuring Tonix Pharmaceuticals, Pop Test Oncology, H. Lundbeck, Bionomics, and Alto Neuroscience
February 29, 2024 11:06 ET | Research and Markets
Dublin, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The "Post-traumatic Stress Disorder (PTSD) - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report...
MAPS Congratulates Lykos Therapeutics on Acceptance of New Drug Application for MDMA-Assisted Therapy for PTSD The FDA has accepted Lykos Therapeutics' New Drug Application, supported by two decades of research incubated by MAPS, for MDMA-assisted therapy for PTSD.
electroCore Expands Intellectual Property Portfolio
January 09, 2024 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...
Webinar Presenter
PTSD: The Brain Basis of Susceptibility - A Free Webinar from the Brain & Behavior Research Foundation
January 03, 2024 09:04 ET | Brain & Behavior Research Foundation
New York, Jan. 03, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “PTSD: The Brain Basis of Susceptibility” on Tuesday, January 9, 2024, at...
Healis Therapeutics Announces Supply Agreement with CKD Bio to develop CKDB-501 for neuropsychiatric indications
January 02, 2024 08:00 ET | Healis Therapeutics
NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, today announced it has entered into a supply agreement with CKD Bio Corporation...
MAPS Celebrates Submission of New Drug Application to FDA for MDMA-Assisted Therapy for PTSD The first NDA submission for any psychedelic-assisted therapy has been submitted through a 30-year effort initiated and led by the nonprofit MAPS
The Virtual Trip Showcases Veterans Sessions from Psychedelic Science 2023 in Honor of Veterans Day Eight virtual conference sessions explore psychedelic research for Veterans including trauma support, federal backing, and a pilot study on Ibogaine
Webinar Presenter
Pediatric PTSD: Neurobiology and Treatment - A Free Webinar from the Brain & Behavior Research Foundation
November 09, 2023 10:28 ET | Brain & Behavior Research Foundation
New York, Nov. 09, 2023 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Pediatric PTSD: Neurobiology and Treatment” on Tuesday, November 14, 2023,...
PharmAla Biotech Logo 800 x 422.png
World’s First Observational Trial to Assess Real-World Efficacy of MDMA Treatment
November 09, 2023 08:55 ET | PharmAla Biotech
PharmAla partners with Heroic Hearts Canada and the University of Calgary to launch the world's first observational rial into MDMA's real-world efficacy